Med-Vet Biolinks Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 54.59%
- Profit Growth 116.05%
- Ebitda -129.37%
- Net Worth 99.01%
- Total Assets 96.38%
About Med-Vet Biolinks
Med-Vet Biolinks Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 November 2018 (Six years and three months 16 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Bhaumik Shah and Aiman Agarwala serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909MH2018PTC317056
- Company No.
317056
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Med-Vet Biolinks?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhaumik Shah  | Director | 14-Nov-2018 | Current |
| Aiman Agarwala | Additional Director | 22-Apr-2019 | Current |
Financial Performance of Med-Vet Biolinks.
Med-Vet Biolinks Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 54.59% increase. The company also saw a substantial improvement in profitability, with a 116.05% increase in profit. The company's net worth Soared by an impressive increase of 99.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Med-Vet Biolinks?
In 2021, Med-Vet Biolinks had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
S. Parikh Pharma Private LimitedBhaumik Shah is a mutual person
- Pharmconnectsolutions Llp
Bhaumik Shah is a mutual person
- Suparshva Pharma Private Limited
Bhaumik Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Med-Vet Biolinks?
Unlock and access historical data on people associated with Med-Vet Biolinks, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Med-Vet Biolinks, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Med-Vet Biolinks's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
